Insight Molecular Diagnostics Inc. (IMDX)

Insight Molecular Diagnostics Inc. (IMDX) is a Diagnostics & Research company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $107M; returns 1 day -0.4%, 1 week -6.0%, 1 year -55.9%.

Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), also known as iMDx, is a precision diagnostics technology company primarily focused on developing and commercializing molecular diagnostic tests for transplant monitoring. The company's core technology quantifies donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to monitor organ transplant rejection and assess organ health.

Groups IMDX belongs to

• Healthcare
• Biotechnology
• Precision Medicine
• Health Diagnostics and Imaging
• Medical Devices
• Organ Transplantation
• Healthcare Technology
• Life Sciences
• Commercial Stage

IMDX financial model: income statement, cash flow and balance sheet